Biopharma
Connexius Biologics SEA 2027
- Date
- 20–21 October 2027
- Location
- Ho Chi Minh City, Vietnam
Event information
- Date
- 20–21 October 2027
- Location
- Ho Chi Minh City, Vietnam
Overview
Southeast Asia's biologics industry is entering a new phase of growth, driven by increasing healthcare demand, expanding biopharma capabilities and greater investment in biologics R&D, development and local manufacturing. Across the region, companies are strengthening capabilities to bring biologic medicines from early-stage research through clinical development, production and ultimately to patients.
Vietnam is emerging as an important part of this evolving ecosystem. The country is working to strengthen its pharmaceutical and biotechnology capabilities, including biologics, biosimilars and vaccines, while encouraging technology transfer, local production and greater collaboration with regional and international partners. Together with established and growing biopharma markets across Singapore, Thailand, Malaysia, Indonesia and the wider Southeast Asian region, this is creating new opportunities across the biologics value chain.
Taking place on 20–21 October 2027 in Ho Chi Minh City, Connexius Biologics SEA 2027 will bring together biopharma and biotech companies, research organisations, manufacturers, CDMOs, logistics partners and technology providers from across Southeast Asia and the wider Asian region.
Covering the journey from biologics discovery and R&D to clinical development, CMC and regulatory strategy, process development and manufacturing, scale-up and technology transfer, cold-chain logistics and commercialisation, the conference will provide a focused platform to exchange expertise, explore new technologies and build partnerships supporting the continued growth of the Southeast Asian biologics ecosystem.
Programme
Day 1 — Wednesday 20 October 2027
- 08:30
Registration & Welcome Coffee
- 09:00
Chairperson's Welcome & Opening Remarks
- 09:10
SESSION I - BIOLOGICS SOUTHEAST ASIA - MARKET, PIPELINE & INDUSTRY OUTLOOK
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION II: BIOLOGICS DISCOVERY, R&D & MOLECULE DEVELOPMENT
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION III: PRECLINICAL, TRANSLATIONAL & CLINICAL DEVELOPMENT
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION IV: CMC, ANALYTICAL DEVELOPMENT & REGULATORY STRATEGY
- 17:00
End of Day 1 — Connexius Biologics SEA 2027, Networking Reception
Day 2 — Thursday 21 October 2027
- 09:10
SESSION V: BIOLOGICS PROCESS DEVELOPMENT & MANUFACTURING
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION VI: SCALE-UP, TECHNOLOGY TRANSFER & MANUFACTURING READINESS
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION VII: BIOLOGICS SUPPLY CHAIN, COLD CHAIN & LOGISTICS
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION VIII: COMMERCIALISATION, MARKET ACCESS & THE FUTURE OF BIOLOGICS IN ASIA
- 17:00
End of Conference
Who Attends
By Company Profile
- Biopharma / Pharmaceutical Manufacturers & Biotech & Big Pharma50%
- Government, NGOs, Research Institutes, Academia & Associations15%
- Solution & Service Providers30%
- Other Industry Stakeholders5%
By Job Function
- Process Development, Bioprocessing & MSAT25%
- Manufacturing, Engineering & Operations20%
- Analytical Development & CMC15%
- Quality & Regulatory Affairs10%
- Biologics R&D / Cell Line / Product Development12%
- Supply Chain, Procurement & Tech Transfer8%
- Business Development / Marketing10%
By Country / Market
- Vietnam40%
- Singapore, Malaysia, Thailand & Indonesia30%
- Philippines & other Southeast Asia5%
- South Korea, Japan, China & Taiwan15%
- India & other international10%
Media Partners
Want to Sponsor This Event?
Explore sponsorship opportunities and discover how your brand can connect with key decision-makers across the industry.
Speak with our Sponsorship Team
Register
Contact us for group bookings of three or more delegates.
| Delegate Category | Super Early Bird Rate Valid until 30th June 2027 | Early Bird Rate Valid 31st August 2027 | Standard Rate |
|---|---|---|---|
| Biopharma, Big Pharma, Academics, Research Institutes & Government | SGD 699 | SGD 899 | SGD 1,099 |
| Service & Solution Provider | SGD 2,049 | SGD 2,249 | SGD 2,449 |
INSIGHTS
Read before you go
- BiopharmaMarket insight
Why Singapore Is Emerging as Biopharma’s China+1 Hub
Singapore’s biopharmaceutical sector is navigating short-term production volatility while strengthening its long-term position as a trusted bridge between China and Western markets. This article examines how Singapore’s regulatory credibility, advanced manufacturing ecosystem and geopolitical neutrality support its emerging role as a China+1 hub for global biopharma.
Read more: Why Singapore Is Emerging as Biopharma’s China+1 Hub - BiopharmaMarket insight
Asia’s Biopharma Manufacturing Landscape Is Changing. Where Are the New Hubs Emerging?
Asia’s biopharmaceutical manufacturing landscape is evolving into a network of specialised ecosystems rather than a single regional hub. This article examines how South Korea, Singapore, China, India, Japan and emerging Southeast Asian markets are developing distinct roles across biologics, advanced therapies and vaccine production.
Read more: Asia’s Biopharma Manufacturing Landscape Is Changing. Where Are the New Hubs Emerging? - BiopharmaIndustry article
Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia
On 12 November 2026, Eppendorf SE broke ground on a new production facility at Bandar Cassia Technology Park in Penang. The EUR 40 million investment is the company's first manufacturing operation in Southeast Asia and will produce selected products from its Centrifuges & Instruments portfolio for laboratories worldwide, with production starting gradually in 2028.
Read more: Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia



